Article
Oncology
Liangping Su, Sangqing Wu, Cheng Huang, Xianhua Zhuo, Jiali Chen, Xue Jiang, Xiangzhan Kong, Cui Lv, Qiuping Xu, Ping Han, Xiaoming Huang, Ping-Pui Wong
Summary: This study uncovers the significance of the interaction between tumor cells and chemoresistant fibroblasts in determining the chemotherapeutic response and prognosis of cancer patients.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Zhengjia Chen, Chao Zhang, Jianhong Chen, Dongsheng Wang, Jieqi Tu, Carter Van Waes, Nabil F. Saba, Zhuo G. Chen, Zhong Chen
Summary: The study found a strong association of FAT1 mutation with altered protein and gene expression in HNSCC patients, particularly in different primary tumor sites. Moreover, the study observed a significant correlation between FAT1 mutation and clinical outcomes, suggesting potential implications for targeted therapies in HPV(-) HNSCC cases.
Article
Cell Biology
Danupon Nantajit, Luana Presta, Thomas Sauter, Mahvash Tavassoli
Summary: EGFR overexpression suppresses cellular proliferation and increases radiosensitivity in HPV-positive HNSCC, while inhibiting EGFR restores BRD4 expression leading to increased HPV E6 and E7 transcription. Targeting EGFR or BRD4 delays cellular proliferation and sensitizes HPV-positive HNSCC cells to ionising radiation. This effect is mediated through EGFR-induced upregulation of microRNA-9-5p and silencing of BRD4.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Amanda E. Yung, Gareth Crouch, Alexander H. R. Varey, Serigne Lo, Michael S. Elliott, Jenny Lee, Robert Rawson, Ruta Gupta, Angela M. Hong, Jonathan R. Clark, Sydney Ch'ng
Summary: More than 60% of patients treated surgically for pT3/4 HNcSCC were alive and free of disease at 5 years posttreatment. High-risk features such as margin involvement and having had previous treatment (radiotherapy/surgery) should be used to guide adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Sachin R. Jhawar, Marcelo Bonomi, Paul M. Harari
Summary: The Oncology Grand Rounds series aims to help readers apply the results of key studies in clinical practice, using case presentations, literature reviews, and treatment recommendations to enhance understanding of the latest developments in oncology.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Morena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Fernando Paragliola, Francesca Sparano, Maria Lucia Iacovino, Anna Castrichino, Francesca Doria, Antonello Sica, Floriana Morgillo, Giuseppe Colella, Giampaolo Tartaro, Salvatore Cappabianca, Domenico Testa, Gaetano Motta, Fortunato Ciardiello
Summary: Head and neck cancers are the seventh most common cancer worldwide, with squamous cell carcinomas being the most frequent histologic subtype. The current standard treatment includes surgery or radiotherapy for early stage diseases, while locally advanced cases may require a more aggressive multi-modal approach. Anti-EGFR targeted therapy cetuximab is currently the only approved targeted therapy option, with the recent development of immune-checkpoint inhibitors providing new treatment options.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kento Okamoto, Toshinori Ando, Hiroki Izumi, Susumu S. Kobayashi, Tomoaki Shintani, J. Silvio Gutkind, Souichi Yanamoto, Mutsumi Miyauchi, Mikihito Kajiya
Summary: The Hippo signaling pathway and its downstream effector YAP play a central role in cell proliferation. Dysregulation of the Hippo pathway triggers YAP hyperactivation, thereby inducing head and neck squamous cell carcinoma (HNSCC). Our findings suggest that co-targeting both AXL and EGFR represent a promising therapeutic approach in patients with EGFR-altered cancers.
Article
Oncology
Treewut Rassamegevanon, Louis Feindt, Lydia Koi, Johannes Mueller, Robert Freudenberg, Steffen Loeck, Wiebke Sihver, Enes Cevik, Ariane Christel Kuehn, Claere von Neubeck, Annett Linge, Hans-Juergen Pietzsch, Joerg Kotzerke, Michael Baumann, Mechthild Krause, Antje Dietrich
Summary: The combination treatment of molecular targeted therapy and external radiotherapy shows promise in improving local tumor control in a HNSCC xenograft model. This study investigates the underlying molecular responses, revealing an increase in DNA double strand breaks and upregulation of genes involved in cell cycle arrest and programmed cell death in tumors treated with the combination therapy.
Article
Biochemistry & Molecular Biology
Tai-Lin Huang, Hui-Ching Chuang, Ming-Hsien Tsai, Chih-Yen Chien, Yan-Ye Su, Yu-Tsai Lin, Chao-Hui Yang, Chi-Chih Lai, Shau-Hsuan Li, Fu-Min Fang
Summary: This study aimed to explore the treatment outcomes and prognostic factors for patients with previously irradiated but unresectable recurrent head and neck squamous cell carcinoma (rHNSCC) treated by stereotactic body radiotherapy (SBRT) plus cetuximab at a single institute in Taiwan. The results showed that the treatment response rate and survival rates were relatively low in this treatment approach, but the re-irradiation interval was found to be a significant prognostic factor for treatment response.
BIOMEDICAL JOURNAL
(2022)
Article
Otorhinolaryngology
Nicole L. Michmerhuizen, Megan L. Ludwig, Andrew C. Birkeland, Sai Nimmagadda, Jingyi Zhai, Jiayu Wang, Brittany M. Jewell, Dylan Genouw, Lindsay Remer, Daniel Kim, Susan K. Foltin, Apurva Bhangale, Aditi Kulkarni, Carol R. Bradford, Paul L. Swiecicki, Thomas E. Carey, Hui Jiang, J. Chad Brenner
Summary: This study identified novel synergistic combinations of EGFR inhibitors with other advanced inhibitors through a high throughput drug screen, showing promising cell activity in resistant models.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Oncology
Pierluigi Bonomo, Isacco Desideri, Monica Mangoni, Calogero Saieva, Mauro Loi, Carlotta Becherini, Cecilia Cerbai, Michele Ganovelli, Viola Salvestrini, Giulia Stocchi, Margherita Zani, Annarita Palomba, Lorenzo Livi
Summary: This study reported on the anti-tumor activity and tolerability of Durvalumab in combination with Cetuximab and radiation for high-risk head and neck squamous cell carcinoma. Optimal drug exposure and high progression-free survival rates were observed.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
John A. Vargo, Vitali Moiseenko, Jimm Grimm, Jimmy Caudell, David A. Clump, Ellen Yorke, Jinyu Xue, Yevgeniy Vinogradskiy, Eduardo G. Moros, Panayiotis Mavroidis, Sheena Jain, Issam El Naqa, Lawrence B. Marks, Dwight E. Heron
Summary: This study systematically reviewed the available literature on tumor control probability with SBRT in head and neck cancer patients, finding a dose-response relationship suggesting better local control and possibly improved overall survival with doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy. It is suggested that SBRT doses equivalent to 5-fraction doses of 40 to 50 Gy are used for retreatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Lihua Shu, Dongsheng Wang, Sreenivas Nannapaneni, Youzhi Sun, Christopher C. Griffith, Xu Wang, Zhengjia Chen, Mihir Patel, Mark El-Deiry, Dong M. Shin, Zhuo G. Chen, Nabil F. Saba
Summary: The study tested the potential ability of tipifarnib to impair proliferation in wild-type H-Ras HNSCC. The results showed that tipifarnib has limited ability to slow tumor growth as a single agent, but the combination with cetuximab enhanced its effects, warranting further research.
Article
Oncology
Yu-Chun Lin, Wen-Yen Huang, Tsai-Yu Lee, Yi-Ming Chang, Su-Feng Chen, Yaoh-Shiang Lin, Shin Nieh
Summary: The study revealed the crucial role of IL-33 in the self-propagation and aggressiveness of HNSCC tumors, and targeting the IL-33-enhanced CXCR4 regulatory circuit can effectively inhibit tumor progression.
Article
Oncology
Jacob Gadwa, Thomas E. Bickett, Laurel B. Darragh, Michael William Knitz, Shilpa Bhatia, Miles Piper, Benjamin Van Court, Shiv Bhuvane, Diemmy Nguyen, Varuna Nangia, Emily K. Kleczko, Raphael A. Nemenoff, Sana D. Karam
Summary: Inhibition of complement C3a and C5a signaling in HNSCC accelerates tumor growth and increases regulatory T cell populations. Local C3a and C5a signaling is important for CD4 T cell homeostasis and development into effector phenotypes. Depletion of Tregs reverses tumor growth and combining Treg depletion with C3a and C5a receptor inhibition reduces tumor growth further.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Athanassios Argiris, Jieling Miao, Mihaela C. Cristea, Allen M. Chen, Jacob M. Sands, Roy H. Decker, Scott N. Gettinger, Megan E. Daly, Bryan A. Faller, Kathy S. Albain, Ronald H. Yanagihara, Linda L. Garland, Lauren A. Byers, Ding Wang, Marianna Koczywas, Mary W. Redman, Karen Kelly, David R. Gandara
Summary: The study evaluated the incorporation of the PARP inhibitor veliparib into chemoradiotherapy for stage III non-small-cell lung cancer. Despite the study ending early, the combination was found to be feasible and well tolerated, although efficacy could not be accurately determined. Promising prospects for further evaluation of PARP inhibitors in lung cancer are highlighted.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
Gregor Manukian, Charles Kivolowitz, Tiziana DeAngelis, Anuradha A. Shastri, Jason E. Savage, Kevin Camphausen, Ulrich Rodeck, Jelani C. Zarif, Nicole L. Simone
Summary: Combining caloric restriction with radiation therapy can reduce intratumoral Tregs, increase the CD8:Treg ratio, and increase PD-1 expression through a process dependent on CD8 T cells. Breast cancer patients undergoing caloric restriction concurrently with radiation therapy also experienced significant reductions in immunosuppressive cytokine levels.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Tu Dan, Anuradha A. Shastri, Ajay Palagani, Simone Buraschi, Thomas Neill, Jason E. Savage, Aastha Kapoor, Tiziana DeAngelis, Sankar Addya, Kevin Camphausen, Renato Iozzo, Nicole L. Simone
Summary: Research has shown that miR-21 plays a crucial role in the development and treatment of breast cancer, with its knockout inhibiting tumor growth and metastasis, and increasing tumor sensitivity to radiotherapy and chemotherapy.
Article
Oncology
Claire Petit, Benjamin Lacas, Jean-Pierre Pignon, Quynh Thu Le, Vincent Gregoire, Cai Grau, Allan Hackshaw, Bjorn Zackrisson, Mahesh K. B. Parmar, Ju-Whei Lee, Maria Grazia Ghi, Giuseppe Sanguineti, Stephane Temam, Maurice Cheugoua-Zanetsie, Brian O'Sullivan, Marshall R. Posner, Everett E. Vokes, Juan J. Cruz Hernandez, Zbigniew Szutkowski, Eric Lartigau, Volker Budach, Rafal Suwinski, Michael Poulsen, Shaleen Kumar, Sarbani Ghosh Laskar, Jean-Jacques Mazeron, Branislav Jeremic, John Simes, Lai-Ping Zhong, Jens Overgaard, Catherine Fortpied, Pedro Torres-Saavedra, Jean Bourhis, Anne Auperin, Pierre Blanchard
Summary: The network meta-analysis suggests that intensifying chemoradiotherapy, using hyperfractionated radiotherapy with concomitant chemotherapy or induction chemotherapy followed by chemoradiotherapy, could improve outcomes for locally advanced head and neck cancer patients.
Article
Oncology
Benjamin Lacas, Alexandra Carmel, Cecile Landais, Stuart J. Wong, Lisa Licitra, Jeffrey S. Tobias, Barbara Burtness, Maria Grazia Ghi, Ezra E. W. Cohen, Cai Grau, Gregory Wolf, Ricardo Hitt, Renzo Corvo, Volker Budach, Shaleen Kumar, Sarbani Ghosh Laskar, Jean-Jacques Mazeron, Lai-Ping Zhong, Werner Dobrowsky, Pirus Ghadjar, Carlo Fallai, Branko Zakotnik, Atul Sharma, Rene-Jean Bensadoun, Maria Grazia Ruo Redda, Severine Racadot, George Fountzilas, David Brizel, Paolo Rovea, Athanassios Argiris, Zoltan Takacsi Nagy, Ju-Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Auperin, Pierre Blanchard, Jean-Pierre Pignon
Summary: The updated results of the study demonstrate the significant improvement in overall survival for head and neck cancer patients with the addition of concomitant chemotherapy, particularly for those with stage III or IV disease. Induction or adjuvant chemotherapy showed less benefit in increasing overall survival. Additionally, efficacy decreases with age progression.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Ioannis A. Vathiotis, Jennifer M. Johnson, Athanassios Argiris
Summary: Anti-programmed cell death protein 1 immunotherapy has become the new standard in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the small population that benefits from this therapy calls for drug combinations and novel approaches. HNSCC is highly immunosuppressive, with ongoing research focusing on potential new targets for combination immunotherapy based on emerging clinical and preclinical data.
CANCER TREATMENT REVIEWS
(2021)
Review
Oncology
Ramez Philips, Chihun Han, Brian Swendseid, Joseph Curry, Athanassios Argiris, Adam Luginbuhl, Jennifer Johnson
Summary: Immunotherapy aims to change the immune interactions in the tumor microenvironment and utilize the host immune system to attack tumor cells, potentially becoming a key component in future treatment. However, preoperative immunotherapy has limitations and requires careful discussion among multidisciplinary treatment teams and patient selection.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Gabriella C. Squeo, Courtney M. Lattimore, Nicole L. Simone, Greg Suralik, Sunil W. Dutta, Michael D. Schad, Lucy Su, Bruce Libby, Einsley-Marie Janowski, Shayna L. Showalter, Jennifer M. Lobo, Timothy N. Showalter
Summary: This study compares the costs of precision breast intraoperative radiation therapy (PB-IORT) between a distributed facility and an integrated brachytherapy suite. The results show that PB-IORT costs less at a distributed facility, with consumable supplies being the largest source of costs.
Article
Oncology
Paolo Bossi, Annalisa Trama, Alice Bernasconi, Salvatore Grisanti, Issa Mohamad, Isabel L. Galiana, Enis Ozyar, Pierfrancesco Franco, Stefania Vecchio, Pierluigi Bonomo, Beatriz C. Cirauqui, Mustafa El-Sherify, Stefano Ursino, Athanassios Argiris, Jonathan Pan, Claus Wittekindt, Elisa D'Angelo, Loredana Costa, Michela Buglione, Jennifer Johnson, Mario Airoldi, Ricard Mesia, Carlo Resteghini, Lisa Licitra, Ester Orlandi
Summary: In non-endemic areas, there is a higher risk of death or recurrence associated with non-intensive treatment (NIT) compared to intensive treatment (IT). Intensive treatment shows benefits for disease-free survival (DFS) in patients with EBER+, but not in patients with EBER-. Additional therapy offers no advantages in EBER- cases.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Nicolas Nelson, Joseph Lombardo, Lauren Matlack, Alexandria Smith, Kamryn Hines, Wenyin Shi, Nicole L. Simone
Summary: Disruption of circadian rhythms is linked to the development and radiation response of breast cancer. Molecular alterations in circadian clock regulators may influence cancer phenotypes, outcomes, and radiation response. Exploiting circadian mechanisms can improve the effectiveness of radiation therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Anuradha A. Shastri, Joseph Lombardo, Samantha C. Okere, Stephanie Higgins, Brittany C. Smith, Tiziana DeAngelis, Ajay Palagani, Kamryn Hines, Daniel A. Monti, Stella Volpe, Edith P. Mitchell, Nicole L. Simone
Summary: Understanding the metabolic and immune regulations inherent to patient populations is crucial to improving radiation response. Patients with poor response to radiation, such as African Americans, obese individuals, or elderly oncology patients, may benefit from concurrent therapies to enhance response. Nutrient deficiencies in these populations should be corrected to optimize the therapeutic index of radiation therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Brenton A. Maisel, Misung Yi, Amy R. Peck, Yunguang Sun, Jeffrey A. Hooke, Albert J. Kovatich, Craig D. Shriver, Hai Hu, Marja T. Nevalainen, Takemi Tanaka, Nicole Simone, Li Lily Wang, Hallgeir Rui, Inna Chervoneva
Summary: The density and spatial relationship of CD163(+) TAMs in tumor tissue are associated with unfavorable prognosis in breast cancer.
Article
Health Care Sciences & Services
Olivia Z. Horgan, Nicole T. Crane, Evan M. Forman, Brandy-Joe Milliron, Nicole L. Simone, Fengqing Zhang, Meghan L. Butryn
Summary: This study aims to assess the feasibility and effectiveness of intervention components designed to improve adherence to dietary guidelines for cancer prevention. The study combines mHealth and traditional methods to promote healthy grocery choices by emphasizing the importance of dietary goals, enhancing motivation, and increasing household support. The results of this study will inform the development of scalable interventions aimed at lowering cancer risk through dietary changes.
JMIR RESEARCH PROTOCOLS
(2022)
Review
Oncology
Ioannis A. Vathiotis, Jennifer M. Johnson, Adam Luginbuhl, David Cognetti, Joseph Curry, Athanassios Argiris
Summary: Immunotherapy, particularly PD-1 inhibitors, has been used in the management of recurrent or metastatic disease and also as part of potentially curative treatment for solid tumors. This review examines the rationale for using immunotherapy in the neoadjuvant and adjuvant settings, reviews the results of clinical trials, and evaluates the potential benefits and caveats of these approaches in SCCHN patients.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Nicolas G. G. Nelson, Joseph F. F. Lombardo, Ayako Shimada, Marissa L. L. Ruggiero, Alexandria P. P. Smith, Kevin Ko, Amy E. E. Leader, Edith P. P. Mitchell, Nicole L. L. Simone
Summary: The LGBTQ+ community faces disparities in cancer screening due to various factors, such as lower screening rates and health literacy gaps caused by systemic barriers. A survey was conducted to understand healthcare providers' experiences, perceptions, and knowledge regarding cancer screening for LGBTQ+ patients. The results showed that despite a lack of formal training, most providers recognized the unique health needs of LGBTQ+ patients. However, there was a lack of consensus among respondents regarding cancer screenings for lesbian and transgender patients, highlighting the need for clearer screening standards and educational programs for LGBTQ+ subpopulations.